Dermatologic events, colitis, and hepatitis are more frequent with CTLA-4 inhibitors, while pneumonitis, thyroid dysfunction, and rheumatologic issues are more common with PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and Hepatitis.